The World Health Organization (WHO) anticipates releasing updated guidance on oral pre-exposure prophylaxis (PrEP), containing tenofovir (TDF), as an additional HIV prevention choice. The new guidance is likely to be significantly broader than previously and creates real opportunities to move forward with implementing PrEP as part of comprehensive HIV programmes. This publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.

The African Union Commission, in cooperation with UNAIDS, undertook to develop a practical guide to assist the African Union Member States, African regional bodies, the African Union Commission and other relevant stakeholders in implementing the Roadmap. The purpose of this guide is to provide practical ideas for how to take the agreed Roadmap agenda forward to achieve rapid results in both reducing the burden of these three diseases and in developing mechanisms to sustain national and regional programmes.

This guide is not a set of prescriptive formulas to be applied uniformly across all African Union Member States. Member States and regional economic communities are encouraged to adapt the suggested actions in this plan to their own contexts and needs, since each country and regional economic community is already carrying out certain interventions and is at different stages of implementing the Roadmap.

Fast-tracking the end of the AIDS epidemic by 2030 requires strong political leadership and commitment to stop new infections and deaths among young women and adolescent girls and eliminate mother to child transmission of HIV. This requires building on, and extending Africa’s commitments on sexual and reproductive health and rights, expanding ministerial commitments on comprehensive sexuality education and stopping early marriage, adolescent pregnancy and expanding treatment service coverage.

This document presents experiences of how community-based antiretroviral therapy (ART) delivery can improve both the level of access to treatment and the quality of health outcomes for people living with HIV. These experiences illustrate that community-based ART delivery is efficient, effective and high quality. This document draws from several Médecins sans Frontières (MSF) reports and articles regarding its experiences with community-supported ART delivery.

The world is uniting around an ambitious HIV treatment target to lay the groundwork to end the AIDS epidemic as a public health threat by 2030. Through national, regional and global-level consultations, diverse stakeholders are pledging to ensure that by 2020: 90% of people living with HIV know their HIV status; 90% of people who know their status receive treatment; 90% of people on HIV treatment have a suppressed viral load.

The report is divided into an overview section that articulates the views of the Chair of the Scientific Expert Panel on the top 10 biomedical research advances in 2014 and five important research findings anticipated in 2015. Thereafter, the report provides brief summaries written almost entirely by Scientific Expert Panel members. The topics are divided into three main categories, advances in the treatment of HIV and comorbidities; advances in HIV prevention; and advances in HIV pathogenesis, diagnostics and cure. Linked to each summary is a bibliography that provides a list of key articles for further reading.

This document is intended for epidemiologists, statisticians and laboratory technicians responsible for the use of HIV incidence assays for surveillance and epidemic monitoring purposes. People that are not technical experts in this field may prefer to first read the UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance published guidelines on When and How to Use Assays for Recent Infection to Estimate HIV Incidence at a Population Level for a basic introduction to this topic.